国产区av中文字幕在线观看-熟女一区二区三区另类激情-免费观看美女无遮挡喷水网站-中日乱码精品一区二区三区软件

技術(shù)文章您現(xiàn)在的位置：首頁 > 技術(shù)文章 > RecombiMAb anti-mouse VEGFR-2抗體

RecombiMAb anti-mouse VEGFR-2抗體

更新時間：2023-10-31   點擊次數(shù)：331次

產(chǎn)品描述：

DC101-CP132單克隆抗體是原始DC101單克隆的重組嵌合型抗體。可變結(jié)構(gòu)域序列與原始DC101相同，但是恒定區(qū)序列已經(jīng)從大鼠IgG1變?yōu)樾∈驣gG2a。DC101-CP132單克隆抗體像原始大鼠IgG1抗體一樣，不包含F(xiàn)c突變。

 

DC101-CP132單克隆抗體能與小鼠VEGFR-2(血管內(nèi)皮生長因子受體2)反應(yīng)，VEGFR-2也稱為CD309、KDR和Flk-1。VEGFR-2是酪氨酸蛋白激酶家族的成員。當結(jié)合到其配體血管內(nèi)皮生長因子時發(fā)揮生理作用，血管內(nèi)皮生長因子受體-2在血管發(fā)育和通透性中起關(guān)鍵作用。血管內(nèi)皮生長因子受體-2在成人心臟、肺、腎、腦和骨骼肌的內(nèi)皮細胞中高表達，在其他組織中低表達。DC101單克隆抗體已被證明在體內(nèi)抑制VEGFR-2信號傳導(dǎo)。

BioXCell熱銷產(chǎn)品--RecombiMAb anti-mouse VEGFR-2

 

產(chǎn)品詳情：

產(chǎn)品名稱

RecombiMAb anti-mouse VEGFR-2

產(chǎn)品貨號

CP132

產(chǎn)品規(guī)格

1/5/25/50/100mg

反應(yīng)種屬

Mouse

克隆號

DC101-CP132

同種型

Mouse IgG2a(switched from rat IgG1)

免疫原

Mouse VEGFR-2-SEAPs soluble receptor

實驗應(yīng)用

in vivo blocking of VEGF/VEGFR-2 signaling*
in vitro blocking of VEGFR signaling*
Western blot*
*Reported for the original rat IgG1 DC101 antibody

產(chǎn)品形式

PBS, pH 7.0,Contains no stabilizers or preservatives

純度

>95%, Determined by SDS-PAGE

聚合

<5%, Determined by SEC

無菌處理

0.2 µm filtration

純化方式

Protein G

分子量

150 kDa

小鼠病原檢測

Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

保存條件

抗體原液保存在4°C，不能冷凍保存。

推薦同型對照

InVivoPlus mouse IgG2a isotype control, unknown specificity（貨號BP0085）

推薦抗體稀釋液

InVivoPure pH 7.0 Dilution Buffer（貨號IP0070）

 

 

 

 

該產(chǎn)品自上市已被多篇SCI文獻引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻引用：

應(yīng)用

文章

體內(nèi)VEGF/VEGFR-2信號阻斷

(in vivo blocking of VEGF/VEGFR-2 signaling)

1. Ding, X., et al. (2015). 'Distinct functions of epidermal and myeloid-derived VEGF-A in skin tumorigenesis mediated by HPV8' Cancer Res 75(2): 330-343.

2. Lee, H. J., et al. (2015). 'Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature' Int J Radiat Oncol Biol Phys 91(3): 621-630.

3. Arulanandam, R., et al. (2015). 'VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection' Cancer Cell 28(2): 210-224.

4. Kizhatil, K., et al. (2014). 'Schlemm’s canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process' PLoS Biol 12(7): e1001912.

體內(nèi)VEGF/VEGFR-2信號阻斷，體外VEGFR信號阻斷

(in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling)

1.Larrayoz, M., et al. (2014). 'Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype' EMBO Mol Med 6(4): 539-550.  

 

 

更多產(chǎn)品詳情請聯(lián)系 BioXCell 中國授權(quán)代理——欣博盛生物